About US
Contact us
-
Lilly exec blasts IRA's 'nonsensical' distinctions as pharma readies legal attacks elsewhereFor many months, thebiopharma industry haslamentedprice-control aspects of the Inflation Reduction Act. Now, Eli Lilly’s R&D chief is openly attacking a controversial clause in the new drug prici2023/5/4
-
Roche's Vabysmo looks to escalate Eylea fight as FDA takes up review in retinal vein occlusionAs Roche's Vabysmo takes a bite out of Regeneron's Eylea sales, the drug has moved one step closer toward an approval in another of its rival drug's uses. The FDA accepted Roche's Vabysmo2023/4/28
-
Let's make a deal: Conditions are right for biopharma M&A to break out, analysts sayPfizer’s proposed $43 billion acquisition of Seagen two months ago was the largest deal in biopharma since 2019. Is it a signal that companies are ready to wheel and deal again? Or is it a false alar2023/4/28
-
With FDA nod, AstraZeneca's Farxiga gains ground in heart failure race with JardianceAstraZeneca’s heart, kidney and diabetes drug Farxiga lagged its Eli Lilly and Boehringer Ingelheim counterpart last year after Jardiance bagged an approval to treat a wider spectrum of heart failure2023/4/26
-
Forge fires up gene therapy production partnership with Life BiosciencesForge Biologics, a genetic medicines manufacturing specialist, inked amanufacturing dealto help Life Biosciences advance its gene therapy platform for age-related diseases. Under the agre2023/4/26
-
After production problems, Catalent delays earnings and plans to slash guidanceFor Catalent, the hits keep coming. After an April communique warning of reduced sales and productivity issues at three separate plants, the CDMO juggernaut delayed the release of its ear2023/4/24
-
As COVID vaccine sales plummet, BioNTech looks for new growth opportunitiesAfter raking in billions with its Pfizer-partnered vaccine, BioNTech is turning to new ventures as its revenues plummet. BioNTech reported first-quarter revenues of 1.27 billion euros (1.2023/4/24
-
Carvykti's massive myeloma win; BeiGene's PD-1 comebackJohnson & Johnson and Legend Biotech's Carvykti showed a massive cancer progression benefit in leaked multiple myeloma trial data. The pair also recruited Novartis to help ramp up supply of the C2023/4/21
-
Johnson & Johnson talc cases put on hold—again—by US bankruptcy courtApplying lessons learned from its first failed bankruptcy for talc lawsuits may produce dividends for Johnson & Johnson. Thursday, U.S. bankruptcy judge Michael Kaplanfrozemore than 32023/4/21
-
BeiGene, Novartis' tislelizumab stages comeback with broader stomach cancer trial winWhen BeiGene and Novartis announced a partial trial win for tislelizumab in stomach cancer, doubts started to circulate around the PD-1 inhibitor’s potential. Now, the partners have come back with br2023/4/19